SCHEMBL15434004

SCHEMBL15434004

COc1cc(C#Cc2cnc(Nc3c(C)cccc3N)nc2)cc(OC)c1

nearest known ligand 0.62

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
▸ FGFR4 P22455 7/20 0.62
▸ ALDH1A1 P00352 1/20 0.37
▸ GRM5 P41594 4/20 0.34
▸ PLAU P00749 1/20 0.34
▸ CHRNA7 P36544 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15434003 0.81 FGFR4 (0.65) FGFR4
SCHEMBL18134023 0.81 FGFR4 (0.51) FGFR4
SCHEMBL15413168 0.81 FGFR4 (0.60) FGFR4ALDH1A1
SCHEMBL15412464 0.77 FGFR4 (1.00) FGFR4
SCHEMBL15434002 0.74 FGFR4 (0.49) FGFR4CHRNA7
SCHEMBL21386689 0.72 CD44 (0.41) —
SCHEMBL15412493 0.70 FGFR4 (0.41) FGFR4ALDH1A1GRM5
SCHEMBL21386622 0.70 FGFR4 (0.65) FGFR4
SCHEMBL21386642 0.70 FGFR4 (0.68) FGFR4
SCHEMBL15611171 0.69 FGFR4 (0.59) FGFR4ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109627239-B Inhibitors of fibroblast growth factor receptors 缆图药品公司 2021-10-12 — — CN disclosed
EP-2872491-B1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR BLUEPRINT MEDICINES CORP (US) 2021-05-05 — — EP disclosed
US-10196436-B2 Inhibitors of the fibroblast growth factor receptor BLUEPRINT MEDICINES CORPORATION (US) 2019-02-05 — — US disclosed
US-20170066812-A1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR BLUEPRINT MEDICINES CORPORATION 2017-03-09 — — US disclosed
WO-2016164703-A1 FGFR4 INHIBITORS EISAI R & D MANAGEMENT CO., LTD. (JP) 2016-10-13 — — WO disclosed
US-9340514-B2 Inhibitors of the fibroblast growth factor receptor BLUEPRINT MEDICINES CORPORATION (US) 2016-05-17 — — US disclosed
US-9126951-B2 Inhibitors of the fibroblast growth factor receptor BLUEPRINT MEDICINES CORPORATION (US) 2015-09-08 — — US disclosed
US-20150210694-A1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR BLUEPRINT MEDICINES CORPORATION (US) 2015-07-30 — — US disclosed
US-20140378481-A1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR BLUEPRINT MEDICINES CORPORATION (US) 2014-12-25 — — US disclosed
US-8802697-B2 Inhibitors of the fibroblast growth factor receptor BLUEPRINT MEDICINES CORPORATION (US) 2014-08-12 — — US disclosed
US-20140187559-A1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR BLUEPRINT MEDICINES CORPORATION (US) 2014-07-03 — — US disclosed
WO-2014011900-A2 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR BLUEPRINT MEDICINES (US) 2014-01-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150210694-A1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR FGFR1, FGFR2, FGFR3 FGFR4 5/4885ALDH1A1 2544/4885GRM5 2284/4885
US-10196436-B2 Inhibitors of the fibroblast growth factor receptor FGFR1, FGFR2, FGFR3 FGFR4 5/4885ALDH1A1 2544/4885GRM5 2284/4885
US-20140378481-A1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR FGFR1, FGFR2, FGFR3 FGFR4 5/4885ALDH1A1 2544/4885GRM5 2284/4885
US-20170066812-A1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR FGFR1, FGFR2, FGFR3 FGFR4 5/4885ALDH1A1 2544/4885GRM5 2284/4885
US-20140187559-A1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR FGFR1, FGFR2, FGFR3 FGFR4 5/4885ALDH1A1 2544/4885GRM5 2284/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback